Clenbuterol affects the expression of messenger RNA for interleukin 10 in peripheral leukocytes from horses challenged intrabronchially with lipopolysaccharides.
- Controlled Clinical Trial
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This study explores how clenbuterol, a medication used to treat breathing disorders, affects the expression of interleukin 10 (IL-10) in horses with small airway diseases when exposed to lipopolysaccharides (LPS), a substance known to stimulate immune responses. It found that clenbuterol suppresses IL-10 expression in these circumstances.
Explanation of Research
The research focuses on the effects of clenbuterol on the expression of various cytokines in horses with respiratory conditions known as heaves and small airway inflammatory diseases. It specifically investigates how this drug interacts with lipopolysaccharides (LPS) to influence the expression of interleukin 10 (IL-10) in the horses’ peripheral leukocytes or white blood cells. The other cytokines studied were tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), and interferon-gamma (IFN-gamma).
- The experiment was conducted on four occasions with four horses diagnosed with heaves and four horses diagnosed with small airway inflammatory diseases.
- The horses inhaled saline-based aerosol mixtures that either contained or did not contain LPS. The LPS was introduced to stimulate an immune response.
- Before the first saline and LPS inhalation, the horses were not given any treatment. However, before the third and fourth inhalation, the horses were given clenbuterol intravenously.
- The researchers then used Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), a molecular biology technique, to analyze the expression levels of the different cytokines in the white blood cells of the horses.
Findings of the Study
The research findings provide valuable insight into the effects of clenbuterol on cytokine expression when the immune system of horses is challenged with LPS.
- The inhalation of LPS only changed the cytokine expression profile for IL-10, IL-4, and TNF-alpha, with the expression of these cytokines being higher after LPS challenge.
- When the horses were treated with clenbuterol, the LPS-induced IL-10 mRNA expression was found to be suppressed.
- There were no significant changes observed in the expression of IL-4 and TNF-alpha after treatment with clenbuterol.
- The study concludes that clenbuterol can modulate, specifically suppress, the expression of IL-10 in horses with small airway diseases exposed to LPS.
This research is important for veterinary medicine as it offers potential approaches to treat respiratory diseases in horses by mitigating the effects of LPS exposure. It also helps in understanding the role of clenbuterol and how it influences the immune response.
Cite This Article
Publication
Researcher Affiliations
- Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, Institute of Medical Chemistry, Veterinary University of Vienna, Veterinärplatz 1, A-1210 Vienna, Austria. Rene.vandenHoven@vu-wien.ac.at.
MeSH Terms
- Animals
- Bronchodilator Agents / administration & dosage
- Bronchodilator Agents / pharmacology
- Bronchodilator Agents / therapeutic use
- Clenbuterol / pharmacology
- Gene Expression Regulation / drug effects
- Horse Diseases / drug therapy
- Horse Diseases / metabolism
- Horses
- Interleukin-10 / genetics
- Leukocytes / drug effects
- Leukocytes / metabolism
- Lipopolysaccharides / administration & dosage
- Lipopolysaccharides / pharmacology
- Lung Diseases, Obstructive / metabolism
- Lung Diseases, Obstructive / veterinary
- Male
- RNA, Messenger / genetics
- RNA, Messenger / metabolism
References
- Vet Immunol Immunopathol. 2003 Jan 10;91(1):45-51
- Vet Immunol Immunopathol. 2002 Mar;85(3-4):147-58
- Vet Immunol Immunopathol. 2002 Sep 25;88(3-4):111-22
- Equine Vet J. 1986 May;18(3):171-8
- J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):191-202
- Agents Actions. 1992 Jan;35(1-2):50-6
- Vet Res Commun. 2002 Feb;26(2):111-26
- Equine Vet J. 2001 May;33(3):311-8
- Equine Vet J Suppl. 2002 Sep;(34):154-8
- Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1410-3
- J Immunol Methods. 1999 Jan 1;222(1-2):155-69
- Equine Vet J. 2001 Nov;33(7):730-3